Philips Releases IntraSight Plus Interventional Guidance System

Philips has launched IntraSight Plus, an intuitive interventional guidance platform. It’s cleared for clinical use in the U.S. and Europe.

The redesigned platform combines comprehensive diagnostic and treatment planning tools so clinicians can diagnose, virtually plan treatment, guide device placement, and verify results all on one screen.

Guidelines support using intravascular ultrasound and physiology for percutaneous coronary intervention (PCI) but systems and inputs are usually separate. Philips said that IntraSight Plus provides an intuitive system that can help save 47% in system operation time and allow total control at the bedside.

Last week, Prof. Dr. Jan-Malte Sinning did the first procedure with IntraSight Plus at Cellitinnen-Krankenhaus St. Vinzenz in Köln, Germany. The hospital recently renewed its cath lab with Philips’ Azurion interventional suites, and the company believes IntraSight plus will further enhance physician workflow.

“Modern PCI is becoming increasingly complex,” said Prof. Dr. Sinning. “Intravascular imaging combined with physiology provides the level of detail we need for contemporary PCI. What stands out with IntraSight Plus is that the platform is clearly designed around how we actually work in the cath lab—combining physiology, imaging and decision-making support in a way that fits naturally into the clinical workflow.”

InstraSight Plus boasts Class IA IVUS and instantaneous wave-free ratio/fractional flow reserve (iFR/FFR) physiology, co-registration, tri-registration and real-time device visualization together in one system.

“As more advanced technology is integrated into the cath lab, the need for connectivity between the imaging tools is more important than ever before,” said Stacy Beske, Business Leader Image Guided Therapy Devices at Philips. “IntraSight Plus was built using feedback from our customers and represents a fundamental shift in interventional cardiology – a future driven by integrated intelligence that lets physicians focus on the decision-making that only they can do.”

Earlier this month, Philips earned U.S. Food and Drug Administration (FDA) 510(k) clearance for SmartHeart, an artificial intelligence (AI)-powered cardiac MR planning solution that the company hopes will help reduce workload on technologists while supporting consistent image quality.